Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 25;12(4):233-241.
doi: 10.5501/wjv.v12.i4.233.

Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load

Gagan Chooramani  1 , Jasmine Samal  1 , Nitiksha Rani  1 , Gaurav Singh  1 , Reshu Agarwal  1 , Meenu Bajpai  2 , Manoj Kumar  3 , Manya Prasad  4 , Ekta Gupta  5
Affiliations

Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load

Gagan Chooramani et al. World J Virol. .

Abstract

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) viral load (VL) estimation is essential for the management of both HBV and HCV infections. Due to a longer turnaround time for VL estimation, many patients drop out from the cascade of care. To achieve the global goals of reducing morbidity and mortality due to HBV/HCV and moving towards their elimination by 2030, molecular diagnostic platforms with faster and random (i.e. single sample) access are needed.

Aim: To evaluate the performance of the recently launched NeuMoDx 96 random access system with the conventional COBAS®AmpliPrep/COBAS TaqMan system for HBV and HCV VL estimation.

Methods: Archived once-thawed plasma samples were retrieved and tested on both platforms. Correlation between the assays was determined by linear regression and Bland-Altman analysis. The study included samples from 186 patients, 99 for HBV of which 49 were true infected HBV cases (hepatitis B surface antigen, anti-hepatitis B core antibody, and HBV DNA-positive) and 87 for HCV assay in which 39 were true positives for HCV infection (anti-HCV and HCV RNA-positive).

Results: The median VL detected by NeuMoDx for HBV was 2.9 (interquartile range [IQR]: 2.0-4.3) log10 IU/mL and by COBAS it was 3.70 (IQR: 2.28-4.56) log10 IU/mL, with excellent correlation (R2 = 0.98). In HCV, the median VL detected by NeuMoDx was 4.9 (IQR: 4.2-5.4) log10 IU/mL and by COBAS it was 5.10 (IQR: 4.07-5.80) log10 IU/mL with good correlation (R2 = 0.96).

Conclusion: The overall concordance between both the systems was 100% for both HBV and HCV VL estimation. Moreover, no genotype-specific bias for HBV/HCV VL quantification was seen in both the systems. Our findings reveal that NeuMoDx HBV and HCV quantitative assays have shown overall good clinical performance and provide faster results with 100% sensitivity and specificity compared to the COBAS AmpliPrep/COBAS TaqMan system.

Keywords: COBAS AmpliPrep; Hepatitis B; Hepatitis C; NeuMoDx; Random access; Viral load.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare having no conflict of interest that pertains to this work.

Figures

Figure 1
Figure 1
Linear regression analysis and Bland-Altman plot. A: Linear regression analysis for correlation of hepatitis B virus (HBV) viral load between assay 1 and assay 2; B: Bland-Altman plot for comparison of HBV viral load between assay 1 and assay 2; C: Linear regression analysis for correlation of hepatitis C virus (HCV) viral load between assay 1 and assay 2; D: Bland-Altman plot for comparison of HCV viral load between assay 1 and assay 2.
See this image and copyright information in PMC

References

    1. World Health Organization. Global hepatitis report 2017. [cited 20 July 2023]. Available from: https://www.who.int/publications/i/item/9789241565455 .
    1. Chen CL, Yang JY, Lin SF, Sun CA, Bai CH, You SL, Chen CJ, Kao JH, Chen PJ, Chen DS. Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol . 2015;63:354–363. - PubMed
    1. Goyal A, Murray JM. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS One . 2014;9:e110143. - PMC - PubMed
    1. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med . 2017;166:637–648. - PMC - PubMed
    1. World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. [cited 20 July 2023]. Available from:https://www.who.int/publications/i/item/progress-report-on-hiv-viral-hep... .